FDA Clears Updated Label for Novartis’ Beovu

The FDA has approved a new label for Novartis’ wet age-related macular degeneration (AMD) treatment Beovu (brolucizumab) with added safety information.

The updated safety section notes the risk of retinal vasculitis or retinal vascular occlusion, two inflammatory conditions that can lead to loss of vision.

The update followed a postmarket review of Beovu by the company after it received some complaints about these adverse events being associated with the drug’s use.